Clinical Trials

88 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

32 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03763162 2026-04-15

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT02106988 2026-04-14

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

26 enrolled

Lymphoma

NCT07480863 2026-04-02

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

65 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04835129 2026-03-27

IMPEDE

28 enrolled

Multiple Myeloma

NCT01297764 2026-03-23

QUAD

17 enrolled

Phase 2/3 Active not recruiting

Multiple Myeloma

NCT02491632 2026-03-18

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

90 enrolled 13 charts

Fatigue, Neoplasm Metastasis, Neoplasms, Recurrence

NCT05690984 2026-03-16

EMAT

30 enrolled

Multiple Myeloma, Neoplasm, Residual

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04094961 2026-03-05

Ixazomib + Pomalidomide + Dexamethasone In MM

52 enrolled

Multiple Myeloma

NCT06203912 2026-03-05

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

3 enrolled

Multiple Myeloma

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

21 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

11 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Phase 3 Active not recruiting

Lymphoma, Mantle-Cell

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

177 enrolled

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT04430894 2026-01-29

KRDI in Transplant-Eligible MM

50 enrolled 20 charts

Multiple Myeloma

NCT05016947 2026-01-29

Venetoclax Plus Inotuzumab for B-ALL

23 enrolled

Phase 3 Active not recruiting

Burkitt Lymphoma, Lymphoma, B-Cell

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03020030 2026-01-22

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

560 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma, Recurrence

NCT03808610 2026-01-09

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

50 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03583255 2025-12-26

Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer

99 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04009109 2025-12-18

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

79 enrolled

Multiple Myeloma

NCT02553460 2025-12-10

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

50 enrolled 12 charts

Phase 2/3 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

790 enrolled

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02427620 2025-11-21

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT05514990 2025-11-14

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

10 enrolled

Multiple Myeloma

NCT00489307 2025-11-12

Dexamethasone for Symptom Burden in Advanced Cancer Patients

132 enrolled 15 charts

Anorexia, Fatigue, Nausea, Pain

NCT03367156 2025-11-12

Dexamethasone in Controlling Dyspnea in Patients With Cancer

135 enrolled 19 charts

Other

Dyspnea, Neoplasms

NCT02253316 2025-11-10

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

236 enrolled 13 charts

Multiple Myeloma

NCT05392946 2025-10-29

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

49 enrolled

Multiple Myeloma

NCT05192889 2025-09-22

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

35 enrolled 12 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

50 enrolled

Multiple Myeloma

NCT01559935 2025-09-08

CarBiRD

74 enrolled 12 charts

Multiple Myeloma

NCT04635189 2025-08-08

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

28 enrolled

Multiple Myeloma

NCT04775550 2025-07-02

PRISM

61 enrolled

Multiple Myeloma

NCT00871013 2025-07-01

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

160 enrolled

Neoplasms, Plasma Cell

NCT00869232 2025-06-29

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

90 enrolled

Multiple Myeloma

NCT01816971 2025-06-10

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

76 enrolled 12 charts

Multiple Myeloma

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

83 enrolled

Multiple Myeloma, Recurrence

NCT03756896 2025-04-30

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

29 enrolled

Multiple Myeloma

NCT04251715 2025-04-18

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Phase EARLY_PHASE1 Active not recruiting

5 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT04895592 2025-03-21

Radiosurgery Before Surgery for the Treatment of Brain Metastases

26 enrolled

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT05479578 2025-01-08

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

7 enrolled

Genitourinary

Castration-Resistant Prostate Carcinoma

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

52 enrolled